SCHEMBL3979426

SCHEMBL3979426

O=C(O)c1scc2c1CCCC2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.62
TP53 P04637 1/20 0.62
KDM4E B2RXH2 3/20 0.53
MAPT P10636 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
LMNA P02545 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
GAA P10253 1/20 0.43
ALDH1A1 P00352 6/20 0.40
POLB P06746 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DAO P14920 1/20 0.35
HTR1A P08908 1/20 0.34
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23334741 0.96 TP53 (0.57) HPGDTP53KDM4EMAPTNPC1
SCHEMBL20892324 0.78 HPGD (0.55) HPGDTP53KDM4EMAPTNPC1
SCHEMBL15778999 0.76 SMN1; SMN2 (0.75) HPGDTP53KDM4EMAPTNPC1
SCHEMBL23335496 0.74 TP53 (0.51) HPGDTP53KDM4EMAPTNPC1
SCHEMBL1857150 0.74 TP53 (0.38) HPGDTP53KDM4EMAPTNPC1
SCHEMBL22336162 0.74 HPGD (0.51) HPGDTP53KDM4EMAPTNPC1
SCHEMBL1856215 0.73 TP53 (0.36) HPGDTP53KDM4EMAPTNPC1
SCHEMBL23334742 0.73 CES1 (0.38) HPGDTP53KDM4EMAPTNPC1
SCHEMBL1854014 0.73 S1PR1 (0.37) HPGDTP53KDM4EMAPTNPC1
SCHEMBL11085849 0.72 MAPT (0.49) HPGDTP53KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110642741-A Functionalized benzamide derivatives as antiviral agents against HBV infection 巴鲁克斯布隆伯格研究所 2020-01-03 CN claimed
US-20150307443-A1 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION BARUCH S BLUMBERG INST (US) 2015-10-29 US claimed
EP-2928459-A2 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION Baruch S. Blumberg Institute (US) 2015-10-14 EP claimed
WO-2014089296-A2 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) 2014-06-12 WO claimed
EP-4640806-A1 WATER-SOLUBLE AUTOMATIC DISHWASHING DETERGENT POUCH The Procter & Gamble Company (US) 2025-10-29 EP disclosed
US-20250326994-A1 WATER-SOLUBLE AUTOMATIC DISHWASHING DETERGENT POUCH PROCTER & GAMBLE (US) 2025-10-23 US disclosed
WO-2025097104-A1 THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER PGI DRUG DISCOVERY LLC (US) 2025-05-08 WO disclosed
CN-118557574-A Dihydroisoxazole compounds for controlling sea lice 瑞士伊兰科动物保健有限公司 2024-08-30 CN disclosed
EP-3466946-B1 THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) 2023-08-30 EP disclosed
WO-2021083182-A1 URICOSURIC AGENT, SYNTHETIC METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF 南京明德新药研发有限公司 2021-05-06 WO disclosed
US-10829483-B2 Thiophene, manufacturing method thereof, and pharmaceutical application of same CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) 2020-11-10 US disclosed
US-20200140423-A1 Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same DONGBAO PURPLE STAR (HANGZHOU) BIOPHARMACEUTICAL CO., LTD (CN) 2020-05-07 US disclosed
EP-1296972-B1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-12-23 EP disclosed
WO-2009060030-A1 HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) 2009-05-14 WO disclosed
EP-2058306-A1 Heteroaryl-substituted 2-pyridinyl-methylamine derivatives SCHWARZ PHARMA AG (DE) 2009-05-13 EP disclosed
US-6977263-B2 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 US disclosed
US-20050228018-A1 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 US disclosed
US-20030187020-A1 Chemical compounds AVENTISUB LLC 2003-10-02 US disclosed
EP-1296972-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2003-04-02 EP disclosed
WO-2001090101-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307443-A1 FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION HAVCR2, PHB2, PHB1 HPGD 2075/4885TP53 2170/4885KDM4E 1371/4885
US-10829483-B2 Thiophene, manufacturing method thereof, and pharmaceutical application of same SLC10A6, TPMT, SLC6A6 HPGD 2842/4885TP53 4012/4885KDM4E 1541/4885
US-20200140423-A1 Thiophene, Manufacturing Method Thereof, And Pharmaceutical Application Of Same SLC10A6, TPMT, SLC6A6 HPGD 2842/4885TP53 4012/4885KDM4E 1541/4885
US-20050228018-A1 Chemical compounds CMA1, TPSB2, TPSG1 HPGD 420/4885TP53 4261/4885KDM4E 3000/4885
US-20030187020-A1 Chemical compounds CMA1, TPSB2, TPSG1 HPGD 420/4885TP53 4261/4885KDM4E 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.